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Summary
Patients with Alzheimer's disease have higher plasma
homocysteine levels than controls, but it is uncertain
whether higher plasma homocysteine levels are
involved in the early pathogenesis of the disease.
Hippocampal, amygdalar and global brain atrophy
on brain MRI have been proposed as early markers
of Alzheimer's disease. In the Rotterdam Scan Study,
a population-based study of age-related brain changes
in 1077 non-demented people aged 60±90 years, we
investigated the association between plasma homocys-
teine levels and severity of hippocampal, amygdalar
and global brain atrophy on MRI. We used axial T1-
weighted MRIs to visualize global cortical brain atro-
phy (measured semi-quantitatively; range 0±15) and a
3D HASTE (half-Fourier acquisition single-shot turbo
spin echo) sequence in 511 participants to measure
hippocampal and amygdalar volumes. We had non-
fasting plasma homocysteine levels in 1031 of the
participants and in 505 of the participants with hip-
pocampal and amygdalar volumes. Individuals with
higher plasma homocysteine levels had, on average,
more cortical atrophy [0.23 units (95% CI 0.07±0.38
units) per standard deviation increase in plasma
homocysteine levels] and more hippocampal atrophy
[difference in left hippocampal volume ±0.05 ml
(95% CI ±0.09 to ±0.01) and in right hippocampal
volume ±0.03 ml (95% CI ±0.07 to 0.01) per stand-
ard deviation increase in plasma homocysteine levels].
No association was observed between plasma homo-
cysteine levels and amygdalar atrophy. These results
support the hypothesis that higher plasma homocys-
teine levels are associated with more atrophy of the
hippocampus and cortical regions in elderly at risk
of Alzheimer's disease.
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Introduction
Patients with Alzheimer's disease or cognitive impairment
have higher plasma homocysteine levels than cognitively
unimpaired older subjects (Clarke et al., 1998; McCaddon
et al., 1998; Lehmann et al., 1999). Recently, a high
plasma homocysteine level was shown to be a strong,
independent risk factor for the development of
Alzheimer's disease (Seshadri et al., 2002). Elevated
plasma total homocysteine level has emerged as a
vascular risk factor (Refsum et al., 1998), and vascular
factors may play an important role in the pathogenesis of
Alzheimer's disease (Breteler, 2000). Furthermore, homo-
cysteine has direct neurotoxic effects on hippocampal and
cortical neurons (Lipton et al., 1997; Kruman et al.,
2000). In Alzheimer patients, homocysteine was associ-
ated with atrophy of the medial temporal lobe and
patients with higher homocysteine levels had a more rapid
rate of atrophy over time (Clarke et al., 1998). Since
Alzheimer's disease is characterized by a long prodromal
period, its aetiology may be better investigated in relation
to early preclinical markers of the disease. Hippocampal,
amygdalar and global brain atrophy on MRI may serve as
such early markers (Cuenod et al., 1993; Jack et al.,
2000; Fox et al., 2001). The aim of this study was to
investigate the association between plasma homocysteine
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This study is based on data collected in the Rotterdam Scan
Study, a population-based cohort study, designed to investi-
gate the determinants and consequences of age-related brain
changes in the elderly (Breteler, 2000). In 1995±1996, we
randomly selected 1904 elderly participants (aged 60±90
years) strati®ed by gender and age (5 years) from two ongoing
population-based cohort studies: the Rotterdam Study
(Hofman et al., 1991) and the Zoetermeer Study (Hofman
et al., 1983). The presence of dementia was assessed in a
stepwise approach as used in the Rotterdam Study (Ott et al.,
1998). First, participants were screened with the Mini-Mental
State Examination and the Geriatric Mental State Schedule.
Those scoring <26 on the Mini-Mental State Examination or
>0 on the Geriatric Mental State Schedule were additionally
assessed with the CAMDEX (Cambridge Examination for
Mental Disorders of the Elderly) interview (Roth et al., 1988).
Subjects thereafter suspected to be demented were examined
by a neurologist. Finally, an expert panel reviewing all
relevant information decided whether an individual was to
be considered demented or not, based on criteria of the
Diagnostic and Statistical Manual (DSM)-IIIR. Additionally,
persons who were blind or had contraindications for MRI
were excluded, leaving 1717 persons eligible. A total of 1077
individuals participated (participation rate of 63%) and gave
written informed consent to a protocol, which was approved
by the medical ethics committee of Erasmus Medical Center,
Rotterdam, The Netherlands.
MRI acquisition
All 1077 participants underwent an axial T1-, T2- and proton
density-weighted brain MRI scan in a 1.5-tesla unit [Philips
(n = 514) and Siemens (n = 563)] (de Groot et al., 2000). For
the 563 subjects originating from the Rotterdam Study
(Hofman et al., 1991), we added a 3D half-Fourier acquisition
single-shot turbo spin echo (HASTE) sequence to the
protocol (inversion time 440 ms, repetition time 2800 ms,
128 contiguous sagittal slices of 1.2 mm, matrix 192 3 256,
®eld of view 256 3 256). Two HASTE modules were
sequentially acquired after the inversion pulse (effective echo
time of 29 and 440 ms), of which the ®rst was used for the
volumetric assessments of the hippocampus and amygdala.
Of the 563 participants, 52 developed claustrophobia, leaving
511 participants with a HASTE sequence.
Hippocampal and amygdalar volumes
The HASTE sequence was used to reconstruct coronal
slices (contiguous 1.5 mm slices) perpendicular to the
long axis of the hippocampus (Fig. 1). The left and right
hippocampus and amygdala were manually traced using a
mouse-driven cursor based on a reference atlas
(Duvernoy, 1998). Tracing proceeded from posterior to
anterior, starting at the slice where the crux of the
fornices was in full pro®le. The in-plane boundaries of
the hippocampus were de®ned to include the subiculum,
the CA1 through CA4 sectors of the hippocampus proper,
and the gyrus dentatus. Tracing of the amygdala included
all of its nuclei. As the anterior boundary of the
amygdala is poorly de®ned in nature, we de®ned this to
be the slice at the rostral extreme of the temporal stem.
Volumes (ml) were calculated [sum of areas (mm2) 3 1.5
mm/1000]. We measured the midsagittal area (cm2) by
tracing the margin of the inner table of the skull in order
to have a proxy for total intracranial volume (Cuenod
et al., 1993). Two readers, who were blinded to clinical
information, measured the 511 scans. Intra- and inter-
reader studies based on 14 random scans showed good
reproducibility. Intrarater intraclass correlation coef®cients
for the left and right hippocampus were r = 0.93 and r =
0.90, and interrater intraclass correlation coef®cients were
r = 0.87 and r = 0.83, respectively. For the left and right
amygdala the intrarater intraclass correlation coef®cients
were r = 0.82 and r = 0.78, the interrater intraclass
correlation coef®cients were r = 0.80 and r = 0.77,
respectively.
Global brain atrophy rating
The severity of global brain atrophy was scored on T1-
weighted hard copies, blinded to clinical information, based
Fig. 1 Coronal slice on which the hippocampus (H) and amygdala
(A) are depicted.
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on the widening of sulci and narrowing of gyri in comparison
to reference scans. A score from 0 (no cortical atrophy) to 3
(severe cortical atrophy) at ®ve different brain regions
(frontal, parietal, temporal and occipital lobes, and insular
region) was given. The sum score of all ®ve regions (range 0±
15) was used for the analyses. The intrarater weighted kappa
was 0.82, and the interrater weighted kappa was 0.81.
Plasma homocysteine measurements
Non-fasting blood samples were collected and processed
at time of MRI as described previously (Vermeer et al.,
2002b). Blood samples were unavailable in 39 partici-
pants due to errors in the blood collection process.
Plasma levels of total homocysteine were determined by
¯uorescence polarization immunoassay on an IMx analy-
ser (Abbott). Seven individuals with extreme values were
excluded from the analyses since their plasma homo-
cysteine levels fell outside the range 5±45 mmol/l in order
to minimize the effects of regression dilution bias.
Finally, 1031 participants were available for the analyses
on global brain atrophy, and 505 participants for the
analyses on hippocampal and amygdalar atrophy.
Covariates
We obtained information on the following covariates by
interview and physical examination in 1995±1996: diabetes
mellitus, hypertension (systolic blood pressure level >160
mmHg, or diastolic blood pressure level >95 mmHg, or use of
blood pressure lowering medication), pack-years of cigarette
smoking, vitamin supplements (Vermeer et al., 2002a) and
serum creatinine levels (enzymatic assay). Presence of carotid
artery plaques, and the intima-media thickness of the common
carotid artery, were assessed as markers of atherosclerotic
disease (Bots et al., 1993). White matter lesions on MRI were
scored in periventricular (grade 0±9) and subcortical regions
(approximated volume) (de Groot et al., 2000). Infarcts on
MRI were de®ned as focal hyperintensities on T2-weighted
images, without prominent hypointensities on T1-weighted
images (Vermeer et al., 2002a).
Data analysis
The relation between plasma homocysteine level and
atrophy was evaluated using both homocysteine in
quintiles and as a continuous variable. Since homocys-
teine levels increase markedly with age, quintiles were
de®ned in an age-speci®c manner for each of the 5-year
age categories. We compared adjusted means of hippo-
campal and amygdalar volumes and global brain atrophy
across the age-speci®c quintiles of plasma homocysteine
by ANCOVA (analysis of covariance). The analyses were
adjusted for age, sex, diabetes, hypertension, pack-years
of cigarette smoking, serum creatinine and, for the
hippocampal and amygdalar analyses, midsagittal area.
Because these analyses did not suggest a non-linear
association between homocysteine and atrophy, we per-
formed multivariate linear regression to calculate the
change in atrophy per standard deviation increase in
plasma homocysteine level. We investigated whether
carotid atherosclerosis, white matter lesions or presence
of infarcts on MRI mediated the association between
homocysteine and atrophy by adding these covariates to
the model. Assumptions of the models were con®rmed by
residual analyses.
Results
Selected characteristics of the total study sample and the
subset with hippocampal and amygdalar volumes are shown
in Table 1.
Plasma homocysteine levels increased with increasing age
(1.5 mmol/l increase per 10 years) and were higher in men
(sex difference 1.2 mmol/l). Sixty-one participants (5.9%)
reported use of multivitamin supplements, and these individ-
uals had lower plasma homocysteine levels than non-users
(age and sex adjusted difference ±1.3 mmol/l; 95% CI ±2.3 to
±0.3).
Figure 2 shows the association between plasma homo-
cysteine levels and hippocampal volumes. People with higher
plasma homocysteine levels had smaller hippocampal vol-
umes [difference in left hippocampal volume ±0.05 (95% CI
±0.09 to ±0.01) and right hippocampal volume ±0.03 (95% CI
±0.07 to 0.01) per standard deviation increase in plasma
homocysteine level adjusted for age, sex, diabetes, hyperten-
sion, pack-years of cigarette smoking, creatinine levels and
midsagittal area]. Further adjustment for carotid athero-
sclerosis, white matter lesions and infarcts did not change this
association (data not shown). In contrast, there was a non-
signi®cant decrease in amygdalar volume with increasing
plasma homocysteine levels (Fig. 3). Per standard deviation
increase in plasma homocysteine level, the left amygdalar
volume decreased ±0.01 (95% CI ±0.04 to 0.03) and the right
Table 1 Characteristics of the total study sample and of
the subset with hippocampal and amygdalar volumes
Characteristic Total Subset
Number 1031 505
Age (years) 72 (7) 73 (8)
Sex (% women) 52 50
Total homocysteine (mmol/l) 11.5 (4.1) 11.9 (4.3)
Presence of diabetes (%) 7 6
Presence of hypertension (%) 52 53
Pack-years of cigarette smoking 19 (24) 20 (25)
Serum creatinine level (mmol/l) 88.9 (18.6) 89.7 (19.9)
Values are unadjusted means (SD) or percentages unless otherwise
speci®ed.
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amygdalar volume decreased by ±0.02 ml (95% CI ±0.05 to
0.02).
Figure 4 shows the association between plasma
homocysteine levels and severity of cortical atrophy.
The degree of cortical atrophy increased with increasing
plasma homocysteine levels [per standard deviation 0.23
units more (95% CI 0.07±0.38)]. This association was
unaltered after adjusting for carotid atherosclerosis [per
standard deviation 0.22 (0.06±0.37)] and slightly weak-
ened after adjusting for white matter lesions and infarcts
[per standard deviation 0.19 (0.03±0.34)].
The results were not materially altered after exclusion of
regular users of multivitamin supplements.
Discussion
This study found that increasing plasma homocysteine levels
are associated with more hippocampal and cortical atrophy in
an older non-demented population.
The chief strength of the present study is the population-
based study design and the large number of volumetric
Fig. 2 Hippocampal volumes according to age-speci®c quintiles of plasma homocysteine levels. The
mean volumes (standard error) are plotted at the median of each quintile and are adjusted for age, sex,
diabetes, hypertension, pack-years of cigarette smoking, creatinine levels and midsagittal area. Note that
the left hippocampus is on average smaller than the right hippocampus.
Fig. 3 Amygdalar volumes according to age-speci®c quintiles of plasma homocysteine levels. The mean
volumes (standard error) are plotted at the median of each quintile and are adjusted for age, sex, diabetes,
hypertension, pack-years of cigarette smoking, creatinine levels and midsagittal area. Note that the left
amygdala is on average smaller than the right amygdala.
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assessments of the hippocampus and amygdala. However, a
limitation was that the instruments used to assess global brain
atrophy were somewhat imprecise.
Plasma homocysteine levels re¯ect vitamin status, renal
function and genetic variations in the enzymes controlling
homocysteine metabolism genes (Refsum et al., 1998).
Recently, it was shown that a low plasma folate level may
predict more neocortical atrophy at death (Snowdon et al.,
2000), although homocysteine may have mediated this
association. There are no available data on effects of genetic
variations in homocysteine metabolism on brain atrophy.
Two putative effects of homocysteine support a causal
association between higher plasma homocysteine levels and
brain atrophy. First, homocysteine damages the vascular
walls (Nappo et al., 1999) from arteries (Selhub et al., 1995;
Fassbender et al., 1999). People with more global brain
atrophy more frequently have atherosclerosis in the carotid
arteries and white matter lesions on MRI, which are assumed
to be small vessel disease (Meguro et al., 1993; Manolio et al.,
1999). However, the association between plasma homocys-
teine levels and atrophy was unaltered by adjusting for carotid
atherosclerosis, and only partly reduced by adjusting for
white matter lesions, suggesting that other pathways may be
involved. Secondly, neurotoxic effects of homocysteine in
cultures of cortical and hippocampal neurons could partly
explain the associations (Lipton et al., 1997; Kruman et al.,
2000). These studies in rats showed that hippocampal neurons
were even more sensitive to the effects of homocysteine
(Kruman et al., 2000) than cortical neurons (Lipton et al.,
1997). Some individuals with hippocampal, and possibly
global, brain atrophy are more likely to develop clinical
Alzheimer's disease (Jack et al., 2000; Fox et al., 2001). The
®ndings of the present study suggest that higher homo-
cysteine levels may be associated with early Alzheimer
pathology. However, due to the cross-sectional design of the
current study, it remains uncertain whether high homocys-
teine levels actually precede changes in pathology and cause
the brain to shrink. Prospective studies using several atrophy
and homocysteine measurements are necessary to unravel
cause and consequence. The ®nding that high baseline
homocysteine levels in patients with Alzheimer's disease
predicted more rapid atrophy of the medial temporal lobe
over the following 3 years supports a causal association
(Clarke et al., 1998). Our results con®rm cross-sectional
studies which show a high plasma homocysteine level to be
associated with Alzheimer's disease and cognitive impair-
ment (Clarke et al., 1998; McCaddon et al., 1998; Lehmann
et al., 1999). Furthermore, they are in keeping with a
prospective study which showed that a high plasma homo-
cysteine level is an independent risk factor for Alzheimer's
disease (Seshadri et al., 2002).
Several large-scale randomized trials with folic acid-based
vitamin supplements to lower homocysteine levels are
currently being conducted and almost all of these trials
include an assessment of cognitive function; some have sub-
studies that also include MRI measurements. Further large-
scale trials are required to assess whether lowering plasma
homocysteine levels may prevent Alzheimer-related struc-
tural abnormalities or delay progression of clinical symptoms
of Alzheimer's disease.
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